O'toole S - Search Results

1

What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.

Cooper WA, O'toole S, Boyer M, Horvath L, Mahar A. Cooper WA, et al. Pathology. 2011 Feb;43(2):103-15. doi: 10.1097/PAT.0b013e328342629d. Pathology. 2011. PMID: 21233671 Review.

2

Molecular assays in breast cancer pathology.

O'Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. O'Toole SA, et al. Pathology. 2011 Feb;43(2):116-27. doi: 10.1097/PAT.0b013e3283430926. Pathology. 2011. PMID: 21233672 Review.

3

Molecular alterations in metaplastic breast carcinoma.

Cooper CL, Karim RZ, Selinger C, Carmalt H, Lee CS, O'Toole SA. Cooper CL, et al. J Clin Pathol. 2013 Jun;66(6):522-8. doi: 10.1136/jclinpath-2012-201086. Epub 2013 Jan 31. J Clin Pathol. 2013. PMID: 23372178 Review.

4

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.

Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MR, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA. Yip PY, et al. J Thorac Oncol. 2013 Apr;8(4):408-14. doi: 10.1097/JTO.0b013e318283558e. J Thorac Oncol. 2013. PMID: 23392229 Free article.

5

Recent insights into the molecular pathogenesis of mammary phyllodes tumours.

Karim RZ, O'Toole SA, Scolyer RA, Cooper CL, Chan B, Selinger C, Yu B, Carmalt H, Mak C, Tse GM, Tan PH, Putti TC, Lee CS. Karim RZ, et al. J Clin Pathol. 2013 Jun;66(6):496-505. doi: 10.1136/jclinpath-2012-201082. Epub 2013 Feb 12. J Clin Pathol. 2013. PMID: 23404800 Review.

6

Therapeutic targets in triple negative breast cancer.

O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A, Oakes SR. O'Toole SA, et al. J Clin Pathol. 2013 Jun;66(6):530-42. doi: 10.1136/jclinpath-2012-201361. Epub 2013 Feb 22. J Clin Pathol. 2013. PMID: 23436929 Review.

7

Classification, morphology and molecular pathology of premalignant lesions of the pancreas.

Cooper CL, O'Toole SA, Kench JG. Cooper CL, et al. Pathology. 2013 Apr;45(3):286-304. doi: 10.1097/PAT.0b013e32835f2205. Pathology. 2013. PMID: 23442735 Review.

8

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B. Selinger CI, et al. Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 Jun 7. Mod Pathol. 2013. PMID: 23743928 Free article.

9

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.

Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen-Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ, O'Toole SA. Cooper WA, et al. J Clin Pathol. 2013 Sep;66(9):744-8. doi: 10.1136/jclinpath-2013-201607. Epub 2013 Jun 11. J Clin Pathol. 2013. PMID: 23757037

10

Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.

Tran TN, Selinger CI, Kohonen-Corish MRJ, McCaughan BC, Kennedy CW, O'Toole SA, Cooper WA. Tran TN, et al. Lung Cancer. 2013 Sep;81(3):462-467. doi: 10.1016/j.lungcan.2013.05.015. Epub 2013 Jun 24. Lung Cancer. 2013. PMID: 23806793

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

458 results

Search Page

Filters